KIM, JUNG KUK,金正国,金正國,KIM, DAE JIN,金大振,HEO, YONG HO,许容豪,許容豪,CHOI, IN YOUNG,崔仁荣,崔仁榮,JUNG, SUNG YOUB,郑圣烨,鄭聖燁,KWON, SE CHANG,权世昌,權世昌
申请号：
TW104117389
公开号：
TW201607553A
申请日:
2015.05.29
申请国别(地区):
TW
年份:
2016
代理人:
摘要：
The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. Morespecifically, concurrent administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administrationof the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the presentinvention relates toadministeringa pharmaceuticalcomposition for reducing side effects ofpancreatic beta cellsindiabeticpatients, including a long-acting insulin analogue conjugate and a long-acting insulinotropic peptide analogue conjugate, and to a method for reducing side effects ofpancreatic beta cellsindiabeticpatients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreaticbeta cellsassociated with thedevelopment of diabetes, reduction in the pancreaticbeta cell mass, lipotoxicity, or glucotoxicity.本發明乃有關用於預防或治療糖尿病之包含長效胰島素接合物與長效促胰島素肽接合物之組成物，及用於治療糖尿病之方法。更具體而言，長效類似物接合物與長效促胰島素肽接合物之同步給藥，抑制由於胰島素給藥之體重增加及由於促胰島素肽給藥之嘔吐與噁心，且亦減少胰島素之需要劑量，從而顯著增進藥物順從性。此外，本發明係有關給藥糖尿病病患減少胰臟β細胞副作用之包含長效胰島素類似物接合物與長效促胰島素肽類似物接合物之醫藥組成物，及有關減少糖尿病病患胰臟β細胞副作用之包括給藥該組成物之步驟之方法。具體而言，本發明之特徵在於減少例如與糖尿病進展相關之胰臟β細胞功能異常、胰臟β細胞質量減少、脂質毒性、或葡萄糖毒性之副作用。
